ADVERTISEMENT

Biocon Q4 Review - Efforts On Multiple Fronts To Aid Strong Earnings Growth: Motilal Oswal

Biocon Q4 Review - Efforts On Multiple Fronts To Aid Strong Earnings Growth: Motilal Oswal

An employee in protective clothing arranges samples inside the research and development center at the Biocon Ltd. campus in Bengaluru, India. (Photographer Dhiraj Singh/Bloomberg)
An employee in protective clothing arranges samples inside the research and development center at the Biocon Ltd. campus in Bengaluru, India. (Photographer Dhiraj Singh/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Biocon Ltd. delivered operationally in-line Q4 FY22. The performance was healthy in generics and research services, while biologics sales have been steady for two quarters now.

Biocon remains on track to develop products as well as build manufacturing capacities across generics and biologics segments to drive robust earnings growth over the next three-four years.

Biocon’ growth outlook remains promising with almost three times earnings over FY22- 24E, driven by market share gain for Insulin Glargine, addition of newer markets for generic formulations, and expanding product portfolio in biologics as well as generics segments.

Click on the attachment to read the full report:

Motilal Oswal Biocon Q4FY22 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.